English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A novel adjuvant (Immunoboost®) to enhance antibody titer response to a commercial vaccine (Lysigin®) against Staphylococcus aureus mastitis in dairy heifers was evaluated. In Phase 1, hyper-immunization with Lysigin® to enhance serum titers did not result in titers that exceeded conventional immunization. In Phase 2, anti-S. aureus titers in heifers immunized with Lysigin® + Immunoboost® tended to be elevated (P = 0.10) over heifers immunized with Lysigin® alone by day (D) 7 continuing through D14. By D21, titers in the Immunoboost® group were elevated (P = 0.05) over conventional vaccinates through D35, returning to baseline by D42. After booster injections on D42, the Immunoboost® group exhibited increased (P = 0.05) titers over conventional vaccinates on D49 through D63, remaining elevated through D84. Findings suggest that Immunoboost® enhanced anti-S. aureus titer responses to commercial vaccination, and support the use of immunization to control S. aureus mastitis in dairy heifers.

Use of a Mycobacterium Adjuvant to Enhance the Antibody Response to Vaccination against Staphylococcus aureusMastitis in Dairy Heifers